ArticleCureus2025
Neuropsychiatric Systemic Lupus Erythematosus With Early-Onset Brain Atrophy: A Case Report and Literature Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuropsychiatric systemic lupus erythematosus (NPSLE) is a serious condition with varied manifestations of systemic lupus erythematosus (SLE) that involves the central and peripheral nervous systems. While seizures and psychiatric components are common findings, brain atrophy is not frequently reported, especially in young individuals. We present a case of a 22-year-old Saudi female who presented with a generalized tonic-clonic seizure and a significant history of undiagnosed psychiatric suffering. Neuroimaging of the brain demonstrated cortical atrophy and extensive subcortical hyperintensities. Autoimmune serology revealed SLE with the positivity of anti-dsDNA and anticardiolipin antibodies. The patient was diagnosed with NPSLE and treated with corticosteroids, hydroxychloroquine, and rituximab. A one-year follow-up MRI showed radiological stability with no new lesions or progression of atrophy. Clinically, she achieved complete seizure remission and improved neurocognitive function. We performed a structured literature review following PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines. Databases were searched, including PubMed, Google Scholar, Springer, and Web of Science, for publications between 2013 and 2025. A total of 1,770 results were screened, and 20 studies were included in the review. The literature review and the case that is discussed support the link between neuroinflammation, injury mediated by autoantibodies, and structural brain changes in NPSLE. Seizures are regularly observed; cortical atrophy is atypical but could represent significant, long-term damage, especially among adults. Immunosuppressive therapy with rituximab can help stabilize both radiological findings and clinically significant manifestations of the disease. This report highlights the necessity of early recognition of neuropsychiatric symptoms in young individuals with an undiagnosed SLE. If an MRI shows central nervous system (CNS) atrophy, then aggressive immunosuppressive therapy is warranted despite the rare nature of findings during clinical presentation. Longitudinal imaging combined with multidisciplinary care may be particularly appropriate, as coordination among the neurologist, rheumatologist, and primary care physician is essential to achieving favorable outcomes in NPSLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.